- In January 2025, GSK plc announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC). The drug is being evaluated for the treatment of adult patients with relapsed or refractory osteosarcoma (bone cancer) who have not responded to at least two prior lines of therapy. Osteosarcoma mainly affects children and young adults and is the most common primary bone cancer
- In January 2025, Pfizer Inc. announced favorable topline results from its pivotal Phase 3 CREST trial, which assessed sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy, with or without maintenance, for patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC)
- In December 2024, GSK plc announced that the US FDA has granted Breakthrough Therapy Designation to Jemperli (dostarlimab-gxly) for the treatment of patients with locally advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer. This designation is intended to accelerate the development and review of drugs that show promise in treating serious conditions, particularly when preliminary clinical evidence suggests a significant improvement over existing therapies
- In October 2024, Sun Pharmaceutical Industries has announced a global licensing agreement with the Italian-Swiss company Philogen for an anti-cancer drug. Under the terms of the deal, Sun Pharma will hold exclusive worldwide rights to commercialize Fibromun, which is currently undergoing registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma
- In October 2024, AbbVie and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement aimed at developing multispecific biologics targeting multiple oncology indications. The discovery partnership will utilize EvolveImmune’s T-cell engager platform to create innovative antibody-based therapies for both solid and hematologic cancers. EvolveImmune's proprietary EVOLVE platform is designed to provide potent, selective, and integrated T-cell co-stimulation, enhancing and sustaining the tumor-killing potential of T-cells
